POLB 001
Alternative Names: HVO-001; POLB-001; UR-13870; UR-138780Latest Information Update: 22 Mar 2024
At a glance
- Originator Uriach
- Developer Centre for Human Drug Research; Palau Pharma; Poolbeg Pharma
- Class Anti-inflammatories; Antivirals; Fluorobenzenes; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- Phase I Cytokine release syndrome; Influenza virus infections
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 20 Mar 2024 Poolbeg Pharma receives patent allowance for POLB 001(Immunomodulator II) in USA
- 09 Dec 2023 Adverse events and pharmacodynamics data from a phase-I trial in Influenza virus infections presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023) (NCT05765955)
- 28 Nov 2023 Phase-I clinical trials in Cytokine release syndrome (unspecified route) before November 2023 (Poolberg pharma pipeline, November 2023)